Not Signed In - Long-term data needed on anti-obesity drugs
Fri, 05 Jan 2007 02:06 PM EST
... NEW YORK (Reuters Health) - The safety and efficacy over the long term need to be documented for Xenical (known generically as orlistat), Meridia (sibutramine) and Acomplia (rimonabant) before doctors can be certain that the benefits of these anti-obesity drugs outweigh the risks, according to a commentary appearing in The Lancet medical journal. ...
Related Topics
- Long Term Care
- Data & Statistics
- Data Analysis
- Acute Care
- Obesity
- National Data
- Overweight and Obesity
- Obesity and Overweight
- Long Term Care/ltc
- Disease-modifying anti-rheumatoid drugs
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Long-term incontinence or urinary retention
- Vegetative state (long-term coma)
- Chronic (long-term) kidney failure
- Complications due to long-term catheter use
- Weak bones (osteomalacia) and osteoporosis (due to very long-term cholestasis)
- Nursing Home Care
- Disabilities
- Wrinkles
- IGF-1
email this page
print this page
bookmark this page
feedback on this page
